250371-80-3

Usage

Type of compound

heterocyclic (contains a six-membered ring with a nitrogen atom)
Contains a fluorine atom and a nitro group

Potential uses

as a building block in the synthesis of more complex organic compounds, or for drug discovery and development due to specific pharmacological properties

Specific uses and properties

depend on the context and the specific application.

Upstream product

• 111-49-9 hexamethylene imine 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 444002-94-2 C₁₂H₁₃FN₂O₃ 
• 250372-47-5 Methanesulfonic acid (R)-3-(4-azepan-1-yl-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 250373-07-0 (R)-3-(4-Azepan-1-yl-3-fluoro-phenyl)-5-azidomethyl-oxazolidin-2-one 
• 250372-26-0 (R)-3-(4-Azepan-1-yl-3-fluoro-phenyl)-5-hydroxymethyl-oxazolidin-2-one 

Relevant academic research and scientific papers

Benzofuroxan Derivatives as Potent Agents against Multidrug-Resistant Mycobacterium tuberculosis

Tuberculosis (TB) is currently the leading cause of death related to infectious diseases worldwide, as reported by the World Health Organization. Moreover, the increasing number of multidrug-resistant tuberculosis (MDR-TB) cases has alarmed health agencies, warranting extensive efforts to discover novel drugs that are effective and also safe. In this study, 23 new compounds were synthesized and evaluated in vitro against the drug-resistant strains of M. tuberculosis. The compound 6-((3-fluoro-4-thiomorpholinophenyl)carbamoyl)benzo[c][1,2,5]oxadiazole 1-N-oxide (5 b) was particularly remarkable in this regard as it demonstrated MIC90 values below 0.28 μM against all the MDR strains evaluated, thus suggesting that this compound might have a different mechanism of action. Benzofuroxans are an attractive new class of anti-TB agents, exemplified by compound 5 b, with excellent potency against the replicating and drug-resistant strains of M. tuberculosis.

PROLINE DERIVATIVES

The invention relates to novel compounds of formula (I), wherein X, Y, R1, R2, R3, R4 and n have the meaning cited in claim 1, are inhibitors of the coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

ARYL UREA DERIVATIVES

A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.

CARBONYL COMPOUNDS

The invention relates to the novel compounds of formula (I), wherein D, E, G, W, X, Y, T, R and R are defined as in claim 1. The inventive compounds inhibit coagulation factor Xa and can be used in the prophylaxis and/or therapy of thrombo-embolic diseases and for treating tumors.

Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 2.1) Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones

5-Thiourea and 5-dithiocarbamate oxazolidinones were synthesized as a continuation of research on 5-thiocarbonyl oxazolidinone antibacterial agents considering the hydrophobic parameters of the molecule. The structure-activity relationship (SAR) study revealed that the antibacterial activity on 5-thiocarbonyl oxazolidinones was significantly affected by the lipophilicity, especially the calculated log P value and the balance between 5-hydrophilic (or hydrophobic) substituent and hydrophobic (or hydrophilic) substituents on the benzene ring. Some of 5-thiocarbonyl oxazolidinones were found to have good in vitro antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).